The presence of stem-like CD8+ T cells correlates with the clinical benefit of anti-PD-1 therapy, and cancer patients who have a higher percentage of stem-like CD8+ T cells experience a longer duration of response to anti-PD-1 antibody14. The gene discussed is CD8A; the disease is cancer.